The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.

The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria - A, C, W and Y ...

The FDA has approved expanded use of Sanofi Pasteur’s MenQuadfi, a meningococcal conjugate vaccine for children aged 2 to 10. MenQuadfi is now the first quadrivalent conjugate vaccine ...

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Sanofi (NASDAQ ...